- Raw materials
- Other substances
- Danegaptide
Danegaptide API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Danegaptide | CAS No: 943134-39-2 | GMP-certified suppliers
A medication that supports research into cardiac arrhythmia treatment by modulating gap junctions to potentially reduce atrial fibrillation and improve cardiac conduction.
Therapeutic categories
Product Snapshot
- Danegaptide is an injectable peptide formulation
- It is primarily investigated for cardiac and neurological therapeutic applications
- The compound currently holds investigational status without approved regulatory market authorization
Clinical Overview
Danegaptide has been primarily investigated in preclinical studies for its potential role in addressing cardiac arrhythmias, notably postoperative atrial fibrillation (AF) and chronic AF in large animal models. The focus of study includes its effects in the context of ST-segment elevation myocardial infarction (STEMI), although a specific clinical indication has not been established or approved.
Pharmacologically, Danegaptide acts as a selective second-generation gap junction modifier with demonstrated oral bioavailability. Its mechanism of action involves enhancing gap junction conductance and coupling, thereby facilitating intercellular communication through improved passage of ions, metabolites, and secondary messengers between adjacent cardiac cells. This modulation of gap junctions helps maintain or restore atrial conduction velocity, particularly under metabolic stress conditions that would otherwise impair electrical signal propagation. In canine models of acute sterile pericarditis, Danegaptide has shown a significant reduction in AF duration and overall AF burden.
Key absorption, distribution, metabolism, and excretion (ADME) parameters have not been extensively characterized or publicly reported, limiting detailed pharmacokinetic profiling at this stage.
Safety and toxicity profiles remain under investigation, with limited published data. As an investigational compound, Danegaptide has not received regulatory approval for clinical use, and comprehensive human safety assessments are pending.
Notable usage contexts currently include experimental and preclinical cardiac arrhythmia models rather than clinical therapeutics. No marketed brand names exist for Danegaptide due to its investigational status.
From an API sourcing perspective, procurement of Danegaptide requires attention to purity specifications, synthetic route reproducibility, and compliance with Good Manufacturing Practice (GMP) standards applicable to investigational pharmaceutical peptides. Analytical characterization should confirm peptide sequence integrity and absence of peptide impurities or degradation products relevant to the therapeutic class.
Identification & chemistry
| Generic name | Danegaptide |
|---|---|
| Molecule type | Small molecule |
| CAS | 943134-39-2 |
| UNII | PA0Y7735AT |
| DrugBank ID | DB11821 |
Pharmacology
| Summary | Danegaptide is a selective gap junction modulator that enhances intercellular communication by increasing gap junction conductance and coupling. It targets atrial tissue to improve conduction velocity and reduce atrial fibrillation duration and burden in preclinical models. Its pharmacodynamic effects involve facilitating the passage of ions and signaling molecules between cardiac cells to stabilize electrical activity. |
|---|---|
| Mechanism of action | Danegaptide, a small modified dipeptide, is a selective second generation gap junction modifier with oral bioavailability. Danegaptide prevents postoperative atrial fibrillation (AF) and chronic AF in large animal models. In a canine model of acute sterile pericarditis, Danegaptide significantly reduced AF duration and overall AF burden. Danegaptide has a similar mechanism of action to its parent compound rotigaptide. Rotigaptide is a synthetic antiarrhythmic peptide (AAP) analogue which has been tested in vitro which shows prevention of prevents metabolic stress-induced atrial conduction velocity (CV) and rapidly reverts established atrial CV slowing. Rogitapeptide enhances gap junction conductance and coupling, increasing the amount of small molecules such as ions, metabolites and secondary messengers passing from one cell to another. |
Formulation & handling
- Danegaptide is a small molecule dipeptide with high water solubility, supporting formulation for aqueous-based delivery systems. Its low LogP value indicates hydrophilic properties, favoring oral or parenteral administration routes. Stability considerations should include protection from hydrolytic degradation given its peptide bond structure.
Regulatory status
Danegaptide is a type of Other substances
The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.
Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.
Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.
Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.
In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.
